Navigation Links
Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
Date:4/2/2011

SAN DIEGO, April 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection (CDI).  The research also presented the substantial mortality and frequent complications associated with CDI.  Investigator Erik R. Dubberke, M.D., M.S.P.H., of the Washington University School of Medicine, St. Louis, Missouri, presented data at the 21st Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA) in Dallas, Texas.  Data for this research were obtained from the 2008 Nationwide Inpatient Sample, 2009 Medicare Provider Analysis and Review file, Florida fiscal year 2006-2007 Medicaid claims and 2007-2008 Medicare 5% Standard Analytical Files.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Dr. Dubberke presented the demographic and clinical characteristics of hospital inpatient CDI cases showing that the average CDI patient was 68 years old, more than half were female, and in total, 83% of CDI cases surveyed were from at least one of the following subpopulations: patients with renal impairment (36%), patients aged greater than age 80 (34%), patients aged 65-79 (33%), cancer patients (16%), inflammatory bowel disease patients (5%), organ transplant patients (2%), human immunodeficiency virus (HIV) patients (1%), or bone marrow transplant patients (0.4%).  Each of these subpopulations are considered to be at high risk of recurrence or mortality from CDI.

Dr. Dubberke also presented data showing that Medicare was the largest payer in the CDI cases surveyed (68%), followed by private insurance (19%), and Medic
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Agena Bioscience TM today announced the ... a commercial and financial hub from which many biotech and ... laboratories in mainland China . ... global sales with almost sixty MassARRAY ® Systems installed ... will allow us to expand our reach and foster a ...
(Date:9/1/2015)... In nur zwei Jahren nach dem ... SHL Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese ... dem Markt der injizierbaren Medikamente und ... von SHL wieder. Foto - ... in Design und Herstellung automatischer Injektoren und Pen-Injektoren ...
(Date:9/1/2015)... WAYNE, Pa. , Sept. 1, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced that researchers will be  presenting scientific data ... Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, ... in development, at PainWeek 2015 to ...
Breaking Medicine Technology:Agena Bioscience Opens Office in Shanghai, China 2SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6
(Date:9/1/2015)... ... September 01, 2015 , ... Splashtop Inc. ... for Remote Support , a solution optimized for MSPs and IT professionals looking ... renewal prices and inadequate customer services of existing remote support solution, many MSPs ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... it is now offering the MonaLisa Touch® , an innovative vaginal health ... MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that ...
(Date:9/1/2015)... ... 01, 2015 , ... The Jerry Segal Classic to benefit the patients of ... Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized ... and services designed to support patients and their families during their time at Magee ...
(Date:9/1/2015)... ... September 01, 2015 , ... Discovia, a leading global provider ... it has hired Scott Sanderson, an experienced business development professional and former NFL ... responsible for establishing and managing new client relationships in the Southeast U.S. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of data loss prevention ... of endpoint DLP developed specifically for Mac OS. , In June 2015, the company ... and information security professionals had participated. The beta test done by the developer community ...
Breaking Medicine News(10 mins):Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Zecurion Announces Endpoint Security for Mac 2
... one of them has developed a flesh eating disease; another ... ,Necrotising fasciitis (flesh eating disease) is a rare infectious, ultimately ... spent five weeks in the hospital, and is released now. ... to the officials that the tattooist has to improve the ...
... discovered a protein interaction that may explain how the ... in and featured on the cover of the current ... Huntington’s protein interacts with another protein to cause dramatic ... ,“Cholesterol is essential for promoting the connection network among ...
... could help in fighting cancer,// a recent study issued an ... prone to a relapse of caner in the following cases: ... stem cells are from a female donor. ,This second ... the original transplant. This is more pronounced in them than ...
... Gene Therapy has published the findings of the first ... dysfunction.// The finding shows that gene therapy negates the ... beneficial for months, and hence could be the most ... author Arnold Melman, M.D., professor and chair of the ...
... has shown, in India, a majority of married women are ... Therefore, there is a definite need for protective methods that ... male-controlled methods are not even 20 percent helpful. ,A ... by over-the-counter microbicides, which are gels, creams, films, or suppositories, ...
... been told that patients undergoing chemotherapy in remote areas may ... the patient sending a text of his symptoms according to ... means of a red alert sent to medical staff, or ... of new age technology may be used along with a ...
Cached Medicine News:Health News:Link Between Huntington’s and Abnormal Cholesterol Levels in Brain Establishe 2Health News:The Other Side of Hematopoietic Stem Cell Transplant 2Health News:Gene Therapy May Be the Solution for Erectile Dysfunction 2
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Anti Gliadin IgG Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... Urinalysis WorkCell System - A Single ... per hour, with true load-and-go productivity ... Clinitek Atlas and UF-100 for complete ... systems working together deliver utmost reliability. ...
... is one of the 3 major naturally ... estrone). In terms of estrogenic activity, estriol ... Estriol is produced almost exclusively during pregnancy, ... the normal human fetus. During pregnancy, the ...
Medicine Products: